https://www.thebodypro.com/category/prep-hiv-pre-exposure-prophylasxis/tag/men-who-have-sex-with-men
PrEP (HIV Pre-Exposure Prophylaxis)

Men Who Have Sex With Men

The Latest

invisible ink

This Week in HIV Research: Missing the Message

May 13, 2021: Disparities in U=U awareness; sexual satisfaction trends among PLWH; PrEP use among cis women; HCV epidemiology in trans women.

By Barbara Jungwirth and Myles Helfand
American teens

This Week in HIV Research: We Need to Better Serve Our Teens

April 8, 2021: PrEP “contemplation” and uptake among adolescents; adolescent perception of HIV risk; HIV diagnosis rates among transgender people; PrEP and HIV incidence in Scotland.

By Barbara Jungwirth and Myles Helfand
Promo Image

This Week in HIV Research: The Unsung Opportunities of Long-Acting Antiretrovirals

March 4, 2021: Improving care for PLWH in transition from incarceration; long-acting PrEP's potential in Black and Latinx communities; comorbidity rates and COVID-19 risk among PLWH; how COVID lockdowns affect the HIV epidemic.

By Barbara Jungwirth and Myles Helfand
magnifying glass

This Week in HIV Research: The Importance of Challenging Our Assumptions

Feb. 25, 2021: High HCV SVR among people using substances; geographic HIV care disparities among Black Americans; self-administered imiquimod vs. ASIL excision; PrEP uptake in syringe service programs.

By Barbara Jungwirth and Myles Helfand
parachute

This Week in HIV Research: What Risk Compensation?

Feb. 4, 2021: STI rates among PrEP users; how Medicaid expansion affects HIV testing and PrEP rates; utilizing mental health care providers in PrEP uptake; adapting HIV care in the COVID era.

By Barbara Jungwirth and Myles Helfand
doctor patient hands

This Week in HIV Research: Health in Unity

Jan. 21, 2021: Dyad-level interventions in serodiscordant relationships; using social media to improve PrEP uptake; HCV prevalence among MSM; the irrelevance of doxycycline prophylaxis against mycoplasma genitalium.

By Barbara Jungwirth and Myles Helfand
green light

U.S. Waits on Approval of Long-Acting HIV Treatment Cabotegravir and Rilpivirine as European Union Gives the Green Light

The era of once-a-month HIV treatment has begun in the European Union—and it may soon commence in the U.S. as well. Long-acting pre-exposure prophylaxis (PrEP) is also on the horizon.

By Michael Broder
Promo Image

This Week in HIV Research: Our Immensely Intersectional Epidemic

Dec. 3, 2020: A simple scoring system for PrEP referral; integrating meth use and HIV prevention interventions; genetically linked HIV strains cross county lines; viral suppression rates in first vs. second pregnancies.

By Barbara Jungwirth and Myles Helfand
chlamydia

DoxyPEP for STIs: Are We Ready for Prophylactic Doxycycline for MSM on HIV PrEP?

A recent expert debate explored the pros and cons of prescribing the antibiotic as a preventive measure for a subset of people at especially high risk for sexually transmitted infections.

By Michael Broder
doctor talking to unrecognizable patient

For PrEP to Work, Shared Doctor-Patient Decision-Making Is Key

The process of choosing between PrEP options is often not straightforward. Oni Blackstock, M.D., explains how providers can help ensure their patients end up with the most successful option for them.

By Terri Wilder, M.S.W.